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Platelet Endothelial Cell Adhesion Molecule-1, a Putative Receptor for
the Adhesion of Streptococcus pneumoniae to the Vascular
Endothelium of the Blood-Brain Barrier
Federico Iovino,a* Grietje Molema,b Jetta J. E. Bijlsmaa
Department of Medical Microbiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlandsa; Department of Pathology & Medical
Biology, Medical Biology Section, University Medical Center Groningen, University of Groningen, Groningen, The Netherlandsb
The Gram-positive bacterium Streptococcus pneumoniae is the main causative agent of bacterial meningitis. S. pneumoniae is
thought to invade the central nervous system via the bloodstream by crossing the vascular endothelium of the blood-brain bar-
rier. The exact mechanism by which pneumococci cross endothelial cell barriers before meningitis develops is unknown. Here,
we investigated the role of PECAM-1/CD31, one of the major endothelial cell adhesion molecules, in S. pneumoniae adhesion to
vascular endothelium of the blood-brain barrier. Mice were intravenously infected with pneumococci and sacrificed at various
time points to represent stages preceding meningitis. Immunofluorescent analysis of brain tissue of infected mice showed that
pneumococci colocalized with PECAM-1. In human brain microvascular endothelial cells (HBMEC) incubated with S. pneu-
moniae, we observed a clear colocalization between PECAM-1 and pneumococci. Blocking of PECAM-1 reduced the adhesion
of S. pneumoniae to endothelial cells in vitro, implying that PECAM-1 is involved in pneumococcal adhesion to the cells. Fur-
thermore, using endothelial cell protein lysates, we demonstrated that S. pneumoniae physically binds to PECAM-1. Moreover,
both in vitro and in vivo PECAM-1 colocalizes with the S. pneumoniae adhesion receptor pIgR. Lastly, immunoprecipitation
experiments revealed that PECAM-1 can physically interact with pIgR. In summary, we show for the first time that blood-borne
S. pneumoniae colocalizes with PECAM-1 expressed by brain microvascular endothelium and that, in addition, they colocalize
with pIgR.We hypothesize that this interaction plays a role in pneumococcal binding to the blood-brain barrier vasculature
prior to invasion into the brain.
Streptococcus pneumoniae (the pneumococcus) is a Gram-posi-tive bacterial pathogen that causes life-threatening invasive
diseases in humans, such as pneumonia and bacteremia. Every
year, over a million people worldwide succumb to diseases caused
by S. pneumoniae (1). Moreover, this bacterium is the most com-
mon causative agent of bacterial meningitis, an inflammation of
the protective membranes covering the brain and spinal cord,
collectively known as the meninges (2, 3). S. pneumoniae is
thought to invade the brain mainly via the bloodstream by cross-
ing the vascular endothelium of the blood-brain barrier, a special-
ized system of endothelial cells that protects the brain from harm-
ful substances that are present in the bloodstream and supplies the
brain with the required nutrients for its proper function (2, 3).
Meningeal pathogens, such as S. pneumoniae and Neisseria
meningitidis, bind to receptors expressed on the plasma mem-
brane of epithelial and endothelial cells, and through this binding,
they can invade and translocate over human cell layers (4–6). The
platelet-activating factor receptor (PAFR) has been described as
one of the major receptors involved in the interaction between S.
pneumoniae and endothelial cells (7–9). Blocking of PAFR leads to
a significant reduction of pneumococcal adhesion to endothelial
cells in vitro, and complete absence of PAFR leads to less invasive
pneumococcal disease in mouse models (4, 7). However, we re-
cently obtained data suggesting that a physical interaction be-
tween S. pneumoniae and PAFR is not likely to occur, as we did not
observe colocalization between the receptor and the bacteria in the
brain tissue of intravenously infected mice (10). Orihuela et al.
showed that the laminin receptor can initiate the contact of S.
pneumoniaewith the brain vascular endothelium in vivo (11). The
polyimmunoglobulin receptor (pIgR) can mediate binding of
pneumococci to the epithelium of the upper respiratory tract (5,
12), and we recently showed new evidence that pIgR is also impli-
cated in binding of S. pneumoniae to brain endothelial cells (10).
At the moment the extent of their contribution is unclear, and it
remains to be established whether more receptors are involved in
pneumococcal adherence to the blood-brain endothelium.
Platelet endothelial cell adhesion molecule-1 (PECAM-1; also
known as CD31) is a panendothelial protein that is present in the
intercellular junctions of the endothelial cells (13, 14). PECAM-1
is involved in leukocyte migration, angiogenesis, and integrin ac-
tivation (13, 14). In particular, the involvement of PECAM-1 in
leukocyte-endothelium interaction and leukocyte transendothe-
lial migration makes PECAM-1 a key molecule in inflammation
and neuroinflammation (15, 16). Recently, PECAM-1 was impli-
cated in Salmonella enterica serovar Typhimurium infections (17),
which raised the question ofwhether PECAM-1 also plays a role in
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host-pneumococcal interactions. Accordingly, the aim of the
present study was to investigate whether PECAM-1 plays a role in
S. pneumoniae adhesion to the endothelium of the blood-brain
barrier. To study this, BALB/c mice were intravenously infected
with S. pneumoniae strain TIGR4 and sacrificed at different time
points preceding meningitis (18), after which we assessed pneu-
mococcal presence and localization in relation to the receptors
studied. In addition, we investigated pneumococcal adhesion to
endothelial cells in vitro. The immunofluorescent and confocal
microscopic analyses of brain sections, in combination with in
vitro blocking experiments and immunoprecipitation assays,
show that PECAM-1 may well be a novel adhesion receptor for
pneumococci that exerts its action in conjunction with pIgR.
MATERIALS AND METHODS
Cell lines, primary cells, and culture conditions. Human brain micro-
vascular endothelial cells (HBMEC; obtained fromK. S. Kim) and human
umbilical vein endothelial cells (HUVEC; obtained from the Endothelial
Cell Facility, UMCG) were cultivated as previously described (19, 20).
Bacterial strains and growth conditions. For the in vivo experiments,
encapsulated S. pneumoniae serotype 4 strain TIGR4 (11, 18) was used.
For the adhesion assays and the in vitro studies on physical interactions
between bacteria and receptors, unencapsulated S. pneumoniae TIGR4
was used (21). The capsule impedes adhesion and invasion into host cells,
yet it also has been shown that S. pneumoniae, in close interaction with
host cells, loses its capsule (4, 21). This is whywe, like others in the field (4,
8, 21), used unencapsulated pneumococci to study the S. pneumoniae-
host cell interactions. The preparations of the challenge dose of encapsu-
lated TIGR4 for themouse experiments and of unencapsulated TIGR4 for
the in vitro experiments were performed as previously described (18, 22).
Bacteremia-derivedmeningitismodel.All experiments involving an-
imals were performed with the prior approval of and in accordance with
guidelines of the Institutional Animal Care and Use Committee of the
University of Groningen (DECno. 6152A). The bacteremia-derivedmen-
ingitis model described by Orihuela et al. (11) was used as described be-
fore (18).
Antibodies and lectin. The antibodies used for immunofluorescent
detection were diluted in sterile phosphate-buffered saline (PBS) with 5%
fetal calf serum (FCS) (Biochrom, Berlin, Germany). The antibody com-
binations are summarized in Table 1.
Immunofluorescent detection. Five-m-thick brain/lung sections
were fixed with acetone for 10min. After 1 h of incubation with unencap-
sulated TIGR4, HBMEC and HUVEC were washed with PBS to remove
nonadherent bacteria and fixed with 4% paraformaldehyde (Sigma-Al-
drich) prior to starting the staining procedure.
After fixation, cells and tissue sections were incubated with primary
antibody for 1 h at room temperature (RT). After washing with PBS,
incubation with secondary antibody for 1 h at RT followed. To detect
nuclei, incubation with 4=,6-diamidino-2-phenylindole (DAPI) for 10
min at RT was performed, and then slides were washed with PBS and
covered with Citifluor solution (Science Services, Munich, Germany).
The slides were analyzed with a Leica DM5500B microscope, and images
were recorded with a Leica DFC 360 FX camera. Before taking each image
with the fluorescence microscope, the fluorescence signal in each channel
was monitored with the Q-LUT function of the program Qwin (Leica
Microsystems), which was used for image processing. The Q-LUT func-
tion shows the signal saturation levels within the areas studied; the over-
saturated signal shows up in red, while the signal that is not oversaturated
remains in grayscale. When the red signal was widespread in the field of
view, the exposure and gain were reduced in order to minimize the over-
saturated signal. The optimal setting was chosen for imaging in order to
get a good overview of the PECAM-1 signal as awhole (in each figure). For
confocal imaging, a Leica SP2 AOBS microscope was used. Immunofluo-
rescent staining steps are summarized in Table 2.
Image processing. The TIFF images obtained with the 350-nm
(blue)-, 488-nm (green)-, and 594-nm (red)-wavelength filters of the
Leica DM5500B fluorescence microscope were merged using the color-
merge channels function in ImageJ (23). The LEI z-stacks obtained with
the Leica SP2 AOBS confocal microscope were merged through Imaris
(Bitplane Scientific Software, Zurich, Switzerland). Brightness and con-
trast were adjusted with the ImageJ function image-adjust-brightness/
contrast in such a way that (i) all images shown in Fig. 1 were adapted by
the same adjustment of brightness and (ii) no information in each image
has been obscured, eliminated, or misrepresented.
Colocalization and bacterial quantification analysis using ImageJ.
The images representing the bacterial and PECAM-1 signals in HBMEC
were analyzed with the ImageJ application named colocalization analysis




S. pneumoniae Anti-capsule serotype 4 antibody (Statens Serum Institute,
Copenhagen, Denmark), diluted 1:200
Alexa Fluor 488 goat anti-rabbit antibody (Invitrogen Life Technologies,
Carlsbad, CA), diluted 1:500
Antipneumococcal antiserum (immunization performed by
Eurogentec, Maastricht, The Netherlands), diluted 1:50
Labeling with Alexa Fluor 350 (Zenon rabbit IgG labeling kit; Invitrogen
Life Technologies)
Endothelial cells DyLight 594-labeled Lycopersicon esculentum lectin (tomato
lectin; Vector Laboratories, Burlingame, VT), diluted
1:200
Rat anti-mouse PECAM-1 antibody (BD Biosciences, Breda,
The Netherlands), diluted 1:50
Alexa Fluor 594 goat anti-rat antibody or Alexa Fluor 488 goat anti-rat
antibody (Invitrogen Life Technologies), diluted 1:500
Mouse anti-human PECAM-1 antibody (Dako), diluted 1:50 Alexa Fluor 594 goat anti-mouse antibody (Invitrogen Life
Technologies), diluted 1:500
Mouse pIgR Goat anti-mouse pIgR antibody (R&D Systems, Abingdon,
United Kingdom) 1:50
Alexa Fluor 488 donkey anti-goat antibody (Invitrogen Life
Technologies), diluted 1:500
Human pIgR Goat anti-human pIgR antibody (R&D Systems, Abingdon,
United Kingdom), diluted 1:50
Alexa Fluor 488 donkey anti-goat antibody (Invitrogen Life
Technologies), diluted 1:500
-Tubulin Mouse anti-human -tubulin (Sigma Aldrich), diluted 1:200 Alexa Fluor 594 goat anti-mouse antibody (Invitrogen Life
Technologies), diluted 1:500
a Mouse IgG (Innovative Research, Plymouth, MA), rat anti-human CD4 (AbD Serotec, Martinsried, Germany), and goat IgG (Santa Cruz Biotechnology, Dallas, TX) were used as
IgG controls for mouse anti-human PECAM-1, rat anti-mouse PECAM-1, and goat anti-mouse/human pIgR, respectively, at the same dilutions as those for the primary antibodies.
Cellular nuclei were stained with DAPI (diluted 1:5,000; Roche, Mannheim, Germany).
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(23). White pixels were automatically generated on the areas of the bac-
terial signal that colocalizedwith the PECAM-1 signal. Using two separate
images, the surface covered by bacteria was measured using the threshold
function of ImageJ (23) by determining the area occupied by the 488-nm
bacterial signal (total bacteria) in the one image and thewhite pixels of the
bacteria colocalizing with receptors in the other.
Western blotting procedure. Human PECAM-1, pIgR (both diluted
1:200), and-tubulin (diluted 1:1,000) were detected byWestern blotting
with the same antibodies that were used for immunofluorescence staining
of human cells. For detection of p53 and F-actin, a mouse anti-p53 anti-
body (Abcam, Cambridge, United Kingdom) and a mouse anti-F-actin
antibody (MerckMillipore, Billerica, United States), each diluted 1:1,000,
were used. Proteins of the HBMEC and HUVEC lysates (prepared as
described below) were separated by SDS-PAGE using NuPAGE gels (In-
vitrogen) and then blotted (75 min, 100 mA per gel) onto a nitrocellulose
membrane (Protran, Schleicher & Schuell, Bath, United Kingdom). Incu-
bation with primary antibodies was followed by incubation with the sec-
ondary antibodies IRDye 800 CW goat anti-mouse (LiCor Biosciences,
Bad Homburg, Germany) for PECAM-1, p53, F-actin, and -tubulin de-
tection and IRDye 800CWdonkey anti-goat (LiCor Biosciences) for pIgR
detection. All secondary antibodies were diluted 1:5,000.
Physical interaction of S. pneumoniae with endothelial proteins.
The lysis buffer consisted of 50mMTris-HCl (Promega,Mannheim, Ger-
many), pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxy-
cholate, 0.1% SDS (all from Sigma-Aldrich), 1 mM EDTA (Merck Milli-
pore, Billerica, MA), and 1 protease inhibitors (Roche, Mannheim,
Germany). Lysis buffer (250 l) was added to confluent monolayers of
HBMEC or HUVEC grown in T25 flasks (TPP, Trasadingen, Switzer-




PECAM-1 and S. pneumoniae in
mouse tissue and human cells
Mixture of anti-PECAM-1 and
anti-capsule serotype 4
antibodies
For mouse tissue, mixture of Alexa Fluor 594 goat anti-rat
and Alexa Fluor 488 goat anti-rabbit; for human cells,
mixture of Alexa Fluor 594 goat anti-mouse and Alexa
Fluor 488 goat anti-rabbit
DAPI (dilution,
1:5,000)
PECAM-1, pIgR, and S.
pneumoniae in mouse tissue
and human cells
Mixture of anti-PECAM-1 and
anti-pIgR antibodies
Mixture of Alexa Fluor 594 donkey anti-mouse and Alexa
Fluor 488 donkey anti-goat antibodies
Anti-capsule serotype 4
antibody labeled
with Alexa Fluor 350
(Zenon kit)
FIG 1 In vivo colocalization of S. pneumoniae and PECAM-1 on brain endothelium. Brain slides of mice systemically infected with S. pneumoniae were
immunofluorescently stained for PECAM-1 (red), pneumococci (green), and cellular nuclei (blue). The images are representative for the situation in each brain
compartment at 1 h (A) and 14 h (B) postbacterial challenge. At 1 h (and 3 h; see Fig. S1 in the supplemental material), no pneumococci were detected in the
choroid plexus. For each time point of infection, 6 brain sections from 3 mice in each group were analyzed. The total magnification of subarachnoid space,
septum, and choroid plexus was630; the total magnification of the cerebral cortex was1,000.
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land). After 1 min of incubation at RT, monolayers were scraped with a
cell scraper (NalgeNunc International, Rochester, United States), har-
vested, and centrifuged at 20,600 rpm for 15 min at 4°C. The supernatant
fractionwas used for further analyses. As a quality control, the lysates were
separated by SDS-PAGE and proteins were visualized by Coomassie bril-
liant blue staining. A solution of approximately 106 CFU of unencapsu-
lated S. pneumoniae TIGR4 was prepared in sterile PBS. Fifty l of
HBMEC or HUVEC lysate was added to 50 l of the bacterial solution,
and the mixture was incubated at 4°C with gentle agitation for 1 h. The
mixture of cell lysate and bacteria then was centrifuged at 20,600 rpm for
20 min at 4°C. The supernatant was removed and the bacterial pellet
washed 2 times with 100 l PBS. After washing, the pellet was incubated
for 1 h at 4°C in 100 l of a mixture of antipneumococcal antiserum and
anti-PECAM-1 antibody in PBS. After washing in PBS, the bacterial pellet
was resuspended in a mixture of Alexa Fluor 488 goat anti-rabbit and
Alexa Fluor 594 goat anti-mouse antibodies (diluted 1:500) in PBS. As
negative controls, mouse anti-human -tubulin/Alexa Fluor 488 goat an-
ti-mouse antibodies were used. Finally, the bacterial pellet was resus-
pended in 100l of distilledwater. Fivel was pipetted onto amicroscope
glass slide and coveredwithCitifluor solution. The slide thenwas analyzed
with a Leica DM5500B fluorescence microscope, and images were re-
corded with a Leica DFC 360 FX camera.
Analysis of PECAM-1 expression in HBMEC andHUVEC.HBMEC
and HUVEC were grown in 12-well plates (TPP) at 37°C with 5% CO2
until confluence. In the case of bacterial adhesion, approximately 107CFU
of S. pneumoniae TIGR4 was added per well. After 1 h of incubation at
37°C at 5% CO2, cells were lysed (see “Physical interaction of S. pneu-
moniae with endothelial proteins”). HBMEC and HUVEC lysates were
analyzed for PECAM-1 protein by Western blotting (see the Western
blotting procedure described above). ImageJ was used to measure the
density of bands of PECAM-1 and -tubulin on Western blot mem-
branes. Rectangles were drawn around PECAM-1 and -tubulin bands.
Using the Analyze/Gels/PlotLanes function, a graphical depiction of the
intensity of pixels from the top of the rectangle to the bottom of the
rectangle was generated, and the areas of each peak of PECAM-1 and
-tubulin bands were calculated. PECAM-1 signal was corrected for the
-tubulin control. Effects of bacterial adhesion on PECAM-1 protein ex-
pression were calculated by dividing the PECAM-1 signal after 1 h of
incubation with pneumococci by the signal under normal conditions.
Pneumococcal adherence to endothelial cells.HBMEC andHUVEC
were grown in 12-well plates (TPP) at 37°Cwith 5%CO2until confluence.
After washing 2 times with PBS, receptor-specific antibodies and a mix-
ture of anti-PECAM-1 plus anti-pIgR antibodies diluted in RPMI were
added to each well to a final concentration of 50 g/ml, and cells were
incubated for 1 h at 37°Cwith 5%CO2. As a control, we usedHBMECand
HUVEC treated with mouse IgG (Innovative Research, Plymouth, MA),
goat IgG (Santa Cruz Biotechnology),mouse IgG plus goat IgGmixture at
50g/ml, or just RPMI. After washing the cells with sterile PBS, 900l cell
culture medium was added to each well and 100 l of approximately 107
CFU/ml of unencapsulated TIGR4 was added. After 1 h of incubation at
37°C under 5% CO2, cells were treated with a 50/50 mix of 1% saponin
(Sigma-Aldrich) and trypsin-EDTA (0.05% to 0.02%) (Gibco) and lysed.
CFU were determined by plating serial dilutions of lysed cells on blood
agar plates. The ratio of adherent bacteria was calculated by dividing the
adherent bacteria by the total amount of bacteria in the well (adherent
plus nonadherent bacteria).
Protein-protein interaction studies. Approximately 5 g of anti-
PECAM-1, anti-pIgR antibody, ormouse IgGwas incubated with 15l of
protein A/G PLUS agarose beads (Santa Cruz Biotechnology) at 4°C for 1
h under gentle agitation. Subsequently, to remove unbound antibody, the
antibody-coated beads were centrifuged at 6,700  g for 30 s at 4°C and
washed with 500 l of the lysis buffer used to make cell lysates. This
procedure was repeated 3 times, and afterwards the pellet was resus-
pended in 50 l of lysis buffer. Aliquots of cell lysates (200 g protein)
were incubatedwith 10l of proteinA/GPLUS agarose beads (SantaCruz
Biotechnology) at 4°C for 1 h under gentle agitation. After centrifugation
at 6,700 rpm for 30 s at 4°C, the supernatants consisting of cleared cell
lysates were mixed with antibody-coated beads and the total mix was
incubated at 4°C for 1 h under gentle agitation. Samples then were centri-
fuged at 8,000 rpm for 30 s at 4°C, and the pellets were washed with 500l
of lysis buffer. This procedurewas repeated 3 times. Lastly, the pellets were
resuspended in 50l of lysis buffer and boiled at 95°C for 5 min. Proteins
in the different samples were separated onNuPAGE gels (Invitrogen) and
then blotted (as described above).
Statistical analysis. SPSS Statistics 20 (IBM) was used for the statisti-
cal analyses of the adherence assay results and the quantitative Western
blot data. The independent-sample t test was used for the analysis of
conditions in which two groups were compared for adherence assay re-
sults (blocking versus isotype control IgG and blocking versus no treat-
ment) and for the analysis of Western blot data of PECAM-1 expression.
In addition, analysis of variance (ANOVA)was used formultigroup com-
parison of the adherence assay data. The Mann-Whitney U test was used
to test whether the reduction of adhesion obtained when PECAM-1 and
pIgR were blocked at the same time was higher than the reduction when
PECAM-1 and pIgRwere blocked separately. Differences were considered
significant when P 0.05 (two-sided test).
RESULTS
S. pneumoniae colocalizes with PECAM-1 expressed by the vas-
cular endothelium of the blood-brain barrier in vivo and by
HBMEC in vitro. Previously we have shown that, as soon as 1 h
after intravenous infection, pneumococci adhere to the blood-
brain endothelium. Since we observed significant spatiotemporal
differences in the invasion of the brain (18), we investigated the
possible colocalization of S. pneumoniae with PECAM-1 at all
time points in all brain compartments during infection. These
immunofluorescent analyses revealed that, at all time points of
infection, more than 95% of adherent bacteria colocalized with
PECAM-1 (Fig. 1A and B; also see Fig. S1A and B in the supple-
mental material). This observation was verified subsequently by
confocal microscopy, which confirmed that S. pneumoniae was
indeed colocalized with PECAM-1 (see Fig. S2). In vitro, colocal-
ization analyses also showed that most pneumococci colocalized
with PECAM-1 in HBMEC cells (Fig. 2). To check for possible
bleed-through between the 488- and 593-nm channels, we also
stained the HBMEC with anti-PECAM-1 antibody only, followed
by Alexa Fluor goat anti-mouse 594 (red). Under this condition,
FIG 2 Colocalization of S. pneumoniae and PECAM-1 in HBMEC. Immuno-
fluorescent detection of S. pneumoniae (green), PECAM-1 (red), and cellular
nuclei (blue) in HBMEC after 1 h of incubation at 37°C with 106 CFU pneu-
mococci. Total magnification, 630. On the right, the areas of the bacterial
signal colocalized with the PECAM-1 signal appear in white (see “Colocaliza-
tion and bacterial quantification analysis using ImageJ” in Materials and
Methods).
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FIG 3 Increased PECAM-1 protein expression in the presence of pneumococci. (A and B) Immunofluorescent detection of tomato lectin (red) and PECAM-1
(green) in the brain ofmock-treatedmice (A) and S. pneumoniae-infectedmice (B) at different time points postinfection. Total magnification,50. Brains from
2mock-treated and 3 S. pneumoniae-infectedmicewere analyzed, and 3 brain sections of eachmousewere analyzed. The images are representative of allmice that
have been analyzed. (C) Expression of PECAM-1 protein in HUVEC and HBMEC under normal conditions and after 1 h of incubation with S. pneumoniae as
assessed by Western blotting. Data represent 3 biological replicates. The molecular masses of PECAM-1 and -tubulin are approximately 120 kDa and 50 kDa,
respectively. Peaks of intensity of PECAM-1 and -tubulin signals generated with ImageJ are also shown. (D) Effects of bacterial adhesion on PECAM-1
expression. Relative PECAM-1 signal in HUVEC and HBMEC under normal conditions and after 1 h of incubation with S. pneumoniae. The y axis shows the
ratios of ImageJ-determined peak intensities of tubulin-corrected PECAM-1 in the absence and presence of bacterial adhesion. *, P 0.05 for HBMEC versus
HBMEC plus bacteria.
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no 488-nm (green) fluorescent signal was detected. We also
stained HBMEC with antipneumococcal antiserum, followed by
Alexa Fluor goat anti-rabbit 488 (green). In this case as well, no
594-nm (red) signal was detected (data not shown).
Our immunofluorescent analyses furthermore showed that in
brain tissue of mock-treated, healthy mice, PECAM-1 signal was
weak and patchy (Fig. 3A), while over the time course of S. pneu-
moniae infection the signal increased. In particular, it seemed that
this increase in PECAM-1 signal was detectable in associationwith
pneumococci or nearby areas where the bacteria were present
(Fig. 3B). This also was observed in the subarachnoid space at 1 h,
cerebral cortex at 8 h, and choroid plexus at 8 and 14 h (see Fig. S2
in the supplemental material). The part of the vasculature associ-
ated with and/or in close proximity to bacteria shows a high PE-
CAM-1 signal, while where bacteria are absent near the vascula-
ture, a low PECAM-1 signal is seen (see Fig. S2).
To investigate whether the presence of bacteria induces an in-
crease in PECAM-1 protein expression, we analyzed by Western
blotting PECAM-1 expression in HBMEC and HUVEC under
normal conditions and after 1 h of incubation with pneumococci.
Upon incubation with bacteria, the level of PECAM-1 in HBMEC
significantly increased, while in HUVEC its levels did not change
(Fig. 3C and D).
To confirm that the PECAM-1 protein levels increased in the
presence of pneumococci and not because of inflammation
caused by bacterial infection, we immunofluorescently stained
PECAM-1 in lung tissue. We previously showed that intravenous
injection of S. pneumoniae TIGR4 causes a high influx of leuko-
cytes in the lungs from1 to 14 h postchallenge, which is a clear sign
of inflammation (18). Between lungs of mock-treated mice and
lungs of infected mice, no differences in PECAM-1 signal were
observed up to 8 h postchallenge (Fig. 4A). Bacteria occasionally
were detected in the lungs only at 14 h postchallenge (Fig. 4B),
which was paralleled by a more intense PECAM-1 expression near
the areas where bacteria were visible (Fig. 4B). Together, these results
suggest that the presence of pneumococci induces PECAM-1protein
expression in the endothelium.
Blocking of PECAM-1 reduces adhesion of S. pneumoniae to
endothelial cells. The immunofluorescent analysis showed colo-
calization between pneumococci and PECAM-1 on brain endo-
thelium in vivo and on brain endothelial cells in vitro. The next
step was to investigate whether PECAM-1 is functionally in-
volved in pneumococcal adhesion to endothelial cells. Indeed,
in HBMEC and HUVEC treated with anti-PECAM-1 antibody
prior to incubation with pneumococci, bacterial adhesion was
45 to 50% reduced compared to the level under control condi-
tions (Fig. 5A and B). This shows that PECAM-1 is involved in the
adherence of S. pneumoniae to endothelial cells in vitro.
Physical interaction between S. pneumoniae and PECAM-1
in endothelial cell lysates. After the observation that blocking of
PECAM-1 with a specific antibody leads to a significant reduction
of pneumococcal adhesion to endothelial cells, we investigated
FIG 4 Specific induction of PECAM-1 in the presence of pneumococci in the lungs. Immunofluorescent detection of PECAM-1 (red) and cellular nuclei (blue)
in lungs of mock-infectedmice (A), during systemic infection with S. pneumoniae up to 8 h postchallenge (B), and in lungs of infectedmice at 14 h postchallenge
(C). No pneumococci were detected in lungs of infected mice up to 8 h postinfection (data not shown). Bacteria were occasionally detected in the lungs at 14 h
postchallenge. Total magnification, 400. Lungs from 3 infected mice were analyzed, and 3 lung sections of each mouse were stained. The images show
representative outcomes for each time point and condition.
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whether S. pneumoniae can physically interact with PECAM-1
present in lysates of endothelial cells. To this end, the bacteriawere
incubated with HBMEC or HUVEC lysates as described previ-
ously (10). In this assay, the bacteria were incubated with a lysate
of cultured cells and collected by centrifugation. After extensive
washing of the bacterial pellet, the bacteria were probed for the
presence of bound eukaryotic proteins from the cell lysate using
immunofluorescence. Indeed, a specific PECAM-1 signal was de-
tected on the surface of pneumococci incubated with HBMEC or
HUVEC (Fig. 6A), which indicates that PECAM-1 protein binds
to pneumococci. In contrast, the control protein -tubulin was not
detected on the pneumococcal cells (Fig. 6B), indicating that in this
assay endothelial proteins generally do not become associated with
the bacteria through nonspecific interactions. As a further control,
bacteria which have not been incubated with endothelial cell lysates
were stainedwith anti-humanPECAM-1 antibody andno signalwas
detected (data not shown). Importantly, these results demonstrate
that S. pneumoniae can physically interact with PECAM-1 protein
that is present in lysates of HBMEC and HUVEC.
PECAM-1 interacts with pIgR, whichmay lead to the forma-
tionof adouble receptor for the adhesionofS. pneumoniae.Our
previous studies have shown that S. pneumoniae is closely associ-
ated with the pIgR receptor on brain endothelial cells and that S.
pneumoniae association with pIgR can facilitate pneumococcal
adherence to endothelium in vitro (10). In light of our present
results, this suggests that pIgR and PECAM-1 should colocalize.
Indeed, confocal imaging showed that PECAM-1 and pIgR are
frequently colocalized in HBMEC and HUVEC when no bacteria
are added (Fig. 7A and B). Furthermore, after incubation with S.
pneumoniae for 1 h, pneumococci adherent to endothelial cells
colocalized with both PECAM-1 and pIgR at the same time (Fig.
7C and D). Immunofluorescent analysis of brain tissues from
noninfected mice also showed that PECAM-1 and pIgR were fre-
quently colocalized in all brain compartments, as did analysis of
brains from infected mice (Fig. 8A to C; also see Fig. S3A and B in
the supplementalmaterial). Lastly,most S. pneumoniae organisms
colocalized with both PECAM-1 and pIgR (Fig. 8B and C; also see
FIG 5 Blocking of PECAM-1 significantly reduces pneumococcal adhesion to
human endothelial cells. Blocking of PECAM-1 with anti-PECAM-1 antibody
(white bars) led to a significant reduction of pneumococcal adhesion to
HBMEC (A) and HUVEC (B) compared to isotype IgG treatment (gray bars)
and untreated HBMEC/HUVEC (black bars). Data represent averages from
triplicate repeats of each condition plus standard deviations and are represen-
tative of three independent experiments. *, P 0.05 for blocking of PECAM-1
versus IgG treatment or no treatment.
FIG 6 S. pneumoniae binds to PECAM-1 inHBMEC andHUVEC lysates. (A) Immunofluorescent detection of S. pneumoniae (green) and PECAM-1 (red) after
pneumococci were incubated with HBMEC and HUVEC lysates. Total magnification, 400. The colocalization of the fluorescence in the overlay (yellow)
indicates that PECAM-1 signal is associated with the pneumococci. (B) Immunofluorescent detection of S. pneumoniae (green) and -tubulin (red) after
pneumococci were incubated with HBMEC and HUVEC lysates. Total magnification,400. The overlay indicates that the -tubulin signal is not detectable on
the pneumococci. Parts of the overlay images (within white rectangles) are enlarged and shown on the right of each figure.
Streptococcus pneumoniae Binds to PECAM-1
September 2014 Volume 82 Number 9 iai.asm.org 3561
 o
n








Fig. S3A and B), strongly supporting the model that PECAM-1
and pIgR both have a role in pneumococcal adherence to brain
microvascular endothelial cells.
To determine whether PECAM-1 and pIgR interact with each
other, we performed immunoprecipitation experiments in which
we pulled down the one protein fromHBMEC or HUVEC lysates
and detected the other one by Western blotting and vice versa.
F-actin, which is known to interact with PECAM-1 (24), was used
as a positive control. p53 was used as a negative control (Fig. 9A),
since there is no evidence in the literature for a direct interaction
between p53 and PECAM-1. Indeed, PECAM-1 and pIgR were
coimmunoprecipitatedwith either antibody,which demonstrated
FIG 7 In vitro, endothelial PECAM-1, pIgR, and S. pneumoniae are colocalized. Confocal imaging of PECAM-1 and pIgR inHBMEC (A) andHUVEC (B) in the
absence of bacteria and inHBMEC (C) andHUVEC (D) after a 1-h incubationwith pneumococci. The overlay shows PECAM-1 being colocalizedwith pIgR. For
each cell type, 10 cells were randomly selected for imaging. Each image shows one cell. The images are representative of the situation in the monolayer.
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that PECAM-1 and pIgR can physically interact in HBMEC and
HUVEC lysates (Fig. 9A and B). Lastly, in vitro blocking data
showed that the adhesion of S. pneumoniae to HBMEC and
HUVEC was more extensively impaired when PECAM-1 and
pIgR were simultaneously blocked than when either PECAM-1 or
pIgR was blocked individually (Fig. 10). All of our data sets to-
gether suggest that PECAM-1 and pIgR cooperatively facilitate the
adhesion of S. pneumoniae to endothelial cells in vitro and to brain
microvascular endothelial cells in vivo.
DISCUSSION
The aimof this studywas to investigatewhether S. pneumoniaehas
the capacity to interact with PECAM-1 protein expressed by vas-
cular endothelium of the blood-brain barrier. To study this, we
mimicked the events preceding meningitis by intravenously in-
fecting mice with pneumococci and sacrificing them at various
time points after challenge (18). In addition, we performed in vitro
bacterial-endothelial adhesion assays. In the course of these anal-
yses, we demonstrated that S. pneumoniae colocalizes with
PECAM-1 in vivo and in vitro, and that PECAM-1 blocking sig-
nificantly reduced the adhesion of S. pneumoniae to endothelial
cells in vitro. In addition, we demonstrated PECAM-1/pIgR colo-
calization with bacteria on brain endothelial cells and showed that
both interact with S. pneumoniae in vitro and are colocalized at the
sites of bacterial adhesion in vivo. Furthermore, coimmunopre-
cipitation studies using endothelial cell extracts showed that PE-
CAM-1 and pIgR can interact. Altogether, these observations im-
ply that PECAM-1 and pIgR proteins canmediate the adhesion of
S. pneumoniae to blood-brain barrier endothelium and possibly
cofacilitate bacterial invasion into the brain.
FIG 8 In vivo, PECAM-1, pIgR, and S. pneumoniae colocalize on brain microvascular endothelium. Immunofluorescent detection of PECAM-1 (red) and pIgR
(green) in brain tissue of mock-treated mice (A) and of PECAM-1 (red), pIgR (green), and S. pneumoniae (blue) in brain tissue of infected mice at 1 h (B) and
14 h (C) postchallenge. The total magnification of the subarachnoid space, septum, and choroid plexus was630; the total magnification of the cerebral cortex
was1,000. Brains from2mock-treated and 3 intravenously infectedmicewere analyzed, and 3 brain sections of eachmousewere used for fluorescence staining.
The images are representative of all mice within the groups that were analyzed.
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Relatively little is known about PECAM-1 as a putative recep-
tor for pathogens. PECAM-1/mice were more resistant to gas-
trointestinal infection with S. Typhimurium than wild-type mice,
resulting in lower bacterial loads in organs such as the liver and the
spleen (17). Whole-bacterial-cell enzyme-linked immunosorbent
assays revealed that human and murine PECAM-1 can bind to S.
Typhimurium, indicating that transmembrane-expressed PE-
CAM-1 is capable of binding to bacteria, which may have patho-
genic consequences (17). In our study, S. pneumoniae was clearly
shown to colocalize with PECAM-1 both in vitro and in vivo, and
incubation of S. pneumoniae with endothelial cell lysates enabled
PECAM-1 to associate with the bacteria. This implies that PE-
CAM-1 also could serve as a receptor for S. pneumoniae, which
may have consequences for the development of invasive pneumo-
coccal disease (IPD). Unequivocal evidence for such a role needs
to be established in future studies employing, for example, endo-
thelium-specific receptor knockout mice.
At present, we do not know which part(s) of S. pneumoniae is
involved in its associationwith PECAM-1. PECAM-1 consists of 6
Ig-like domains. In the literature, it has been shown that specific
components of S. pneumoniae, such as the major pilin RrgB,
which forms the pilus shaft on the bacterium, and the keratin
10-binding domain of the adhesin PsrP contain Ig-like domains
(25, 26). Furthermore, it has been shown that Ig-like domains can
react with a variety of different domain types; in particular, inter-
actions with other Ig-like domains are the most frequent (27).
Thus, one hypothesis is that the Ig-like domains present on S.
pneumoniae and on PECAM-1 mediate the physical interaction
between PECAM-1 and the bacteria.
As shown by immunofluorescence, PECAM-1 protein is ex-
pressed in the healthy mouse brain, although relatively weakly
(Fig. 3A). Upon pneumococcal infection, the PECAM-1 signal
increased, in particular when S. pneumoniae was associated
with/in close proximity to the cells (Fig. 3B). Using lung tissues of
the same mice, we showed that inflammation per se is not enough
to induce the PECAM-1 signal and that the presence of the bacte-
ria is needed. Together with the increased PECAM-1 expression
by HBMEC upon bacterial adhesion, this implies that the induc-
tion of this receptor is a direct consequence of bacterial binding to
the receptor. Additional experiments will be needed to further
establish whether such a causal role between bacterial binding and
(transcriptional or posttranscriptional) control of PECAM-1 ex-
pression exists and whether the induction has functional conse-
quences.
After intravenous injection of 107 CFU of S. pneumoniae
TIGR4, the systemic numbers of bacteria were reduced by 10-fold
at 1 h after the challenge (18), but as the disease progressed, the
recoverable CFU in the blood increased, corroborating a previ-
ously reported study in a rabbit model (28). PECAM-1 is ex-
pressed by the endothelial cells of the entire vascular system (14),
so it may be possible that this initial 10-fold drop in CFU in the
blood within the first hour is the result of an immediate attach-
FIG 9 PECAM-1 interacts with pIgR in HBMEC and HUVEC lysates. (A) Immunoprecipitation of PECAM-1 and pIgR followed by Western blotting showed
that PECAM-1 interacts with pIgR present in HBMEC and HUVEC lysates as well as with F-actin, while no interaction with p53 is detectable. (B) Immunopre-
cipitation of pIgR inHBMEC andHUVEC lysates followed by detection of PECAM-1. (C) Control immunoprecipitation withmouse IgG-coated beads does not
show a PECAM-1 signal. Data represent 3 biological replicates.
FIG 10 Blocking of PECAM-1 and pIgR reduces the pneumococcal adhesion
to human endothelial cells to lower levels than blocking of the individual
receptors. Blocking of PECAM-1, pIgR, and PECAM-1 plus pIgR in HBMEC
(white columns) and HUVEC (gray columns) leads to a significant reduction
of pneumococcal adhesion compared to that of controls treated with the re-
spective isotype IgG. The adhesion ratio of controls was set at 1 and is indicated
by the black dashed line. Treatment with specific receptor antibodies signifi-
cantly reduced adhesion compared to that of controls in both HBMEC and
HUVEC. *, P 0.05. When both receptors are blocked at the same time, the
reduction of pneumococcal adhesion is higher than that when blocking the
individual receptors in both HBMEC and HUVEC. §, P 0.05.
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ment of bacteria to PECAM-1 in all blood vessels or in specific
compartments of the body, whichwould sequester the bacteria. In
principle, the immediate attachment of bacteria to the vascula-
turesmay lead to bacterial invasion into these organs. However, S.
pneumoniae is known mainly to cause pneumonia, bacteremia,
otitis media, and meningitis. Therefore, it would be interesting to
investigate in future studies whether blood-borne pneumococci
also are able to translocate over the endothelium of other organs
or whether they are protected from invasion by (unknown) mo-
lecular mechanisms that are lacking in the pathogenically pre-
ferred sites.
Receptor-mediated adhesion to human cells is a mechanism
also described in meningeal invasion by N. meningitidis. It was
reported that type IV pili of meningococci adhere first to a recep-
tor, possibly PAFR (29), and afterwards to the -adrenoceptor
expressed on the cell membrane of HBMEC. These two receptors
together allow meningococci to adhere to and traverse the endo-
thelial cells, leading to invasion of the brain (6, 29). A similar
receptor cooperation concept also may apply to S. pneumoniae
adhesion to and invasion of endothelial cells of the blood-brain
barrier. Here, we show that pIgR and PECAM-1 colocalize in the
healthy murine brain and in the presence of infectious bacteria.
Furthermore, blocking of both receptors with specific antibodies
reduces pneumococcal adhesion approximately 20% more than
blocking each receptor separately.Moreover, the immunoprecipi-
tation analyses show that PECAM-1 and pIgR are capable of in-
teracting with each other. Thus, it may well be that these two
proteins form a double receptor on the plasma membrane of en-
dothelial cells, which may have a functional consequence for bac-
terial adhesion to the endothelium and possibly also for further
endothelial engagement in the S. pneumoniae translocation pro-
cess.
To unequivocally demonstrate a role for these receptors per se
in S. pneumoniae pathology, intravenous challenges with S. pneu-
moniae in PECAM-1/ mice and pIgR/ mice should be per-
formed. In the case of a direct role, the prediction is that fewer
bacteria would translocate the blood-brain barrier in the knock-
out mice; accordingly, meningitis symptoms should be reduced.
Lastly, systemic challenges in mice lacking both PECAM-1 and
pIgR should be performed to determine whether pneumococcal
adhesion to the brain endothelium and disease symptoms are di-
minished to a greater extent in the double mutant mice than in
mice lacking only one receptor. This would establish not only
whether but also to what extent the two receptors cooperate and
whether this has functional and pathological consequences.
In conclusion, based on the data presented, we propose that
pneumococci in the bloodstream can bind PECAM-1 and/or pIgR
expressed by brain microvascular endothelial cells, and that these
two receptors on the plasmamembrane of endothelial cells further
facilitate the bacterial adhesion process. Additional experiments
are needed to shed light on the functional role of both receptors in
facilitating S. pneumoniae invasion into the brain in vivo and to
answer the question of whether their blockade has any therapeutic
advantage for patients with bacteremia and meningitis.
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